PPARγ agonists, which influence the WNT/β-catenin pathway and inflammatory processes, represent a potential therapeutic strategy, although more research is required to validate their efficacy and mechanism of action in the context of schizophrenia [6]. Here, PPARG is linked to schizophrenia.